Category Archives: Product-by-Process

Grant of JMOL reversed as “an old method of administration of an old product made by a new process is not novel and cannot be patented”

Biogen MA Inc. v. EMD Serono, Inc. et al. (Pfizer Inc., Bayer, Novartis) Docket No. 2019-1133 NEWMAN, LINN, HUGHES September 28, 2020 Brief Summary:  DC instructed to reinstate jury verdict of invalidity for anticipation of Biogen’s IFN-b method of treatment … Continue reading

Posted in Anticipation (35 USC 102), Product-by-Process, Uncategorized | Leave a comment

In re: Nordt Development Co., LLC

Docket Nos. 2017-1445 MOORE, TARANTO, STOLL February 8, 2018 Brief summary: PTAB decision based on construction of “injection molded” as a product-by-process limitation vacated and remanded as “the structural nature of ‘injection molded’ can be gleaned from the plain claim … Continue reading

Posted in Claim Construction, Product-by-Process | Leave a comment